Company Profile
NervGen Pharma Stock Price, News & Analysis
- Ticker:
- NGEN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Canada and listed in the U
Stock performance
1.61 USD (-1.83%)
Close
Last updated: July 28, 2026
212M USD
Market cap
Why the stock is moving
As of Jul 28, 2026, NGEN closed down 1.83% at $1.61. No new same-company headline was identified in the current news window.
Company overview
Business overview
NervGen Pharma is a biotechnology company focused on nerve repair and neurologic recovery. Its story centers on translating neuroscience and regeneration biology into therapies for damaged or impaired nerves.
Geographic Base and Sector Classification
NervGen is headquartered in Canada and listed in the U.S. market. It sits in neuroscience and regenerative biotechnology.
Business Model Characteristics
The company depends on preclinical and clinical progress, translational confidence, and the ability to keep a narrow program funded. Investors usually watch early data and strategic developments.
Position Within the Biotechnology Landscape
NervGen occupies a niche nerve-repair position within biotech. It is a catalyst-sensitive early-stage name because the company is still proving whether the biology can translate.
Future catalysts
NervGen’s catalysts are NVG-291 and the neuroregeneration program, where the next update can materially move the story. The company still needs proof that the biology can translate.
Recent news
- 01
- 02
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
Source: NervGen Pharma
- 03
NervGen Announces Proposed Public Offering of Securities
Source: NervGen Pharma
- 04
NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
Source: NervGen Pharma
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of NervGen Pharma (NGEN)?
NervGen Pharma (NGEN) most recently closed at 1.61 USD, a -1.83% move versus the previous session.
What is the market cap of NervGen Pharma (NGEN)?
NervGen Pharma currently has a market capitalization of 212M USD on BioPharmSignal.
What does NervGen Pharma do?
NervGen Pharma is a biotechnology company focused on nerve repair and neurologic recovery. Its story centers on translating neuroscience and regeneration biology into therapies for damaged or impaired nerves.
On which exchange is NGEN stock listed?
NervGen Pharma (NGEN) is associated with NASDAQ, Canada and listed in the U, Biopharma.
What is NVG-291?
NervGen’s catalysts are NVG-291 and the neuroregeneration program, where the next update can materially move the story.
Which conditions is NervGen Pharma targeting with NVG-291?
NervGen Pharma is associated with neuroscience based on its company overview and current catalyst commentary.
How does NervGen Pharma describe recent progress with NVG-291?
NervGen’s catalysts are NVG-291 and the neuroregeneration program, where the next update can materially move the story.
What is NervGen?
NervGen Pharma is a biotechnology company focused on nerve repair and neurologic recovery.